Charmingly eccentric, full of personality, and designed for maximum reader engagement
Bausch Health Canada Inc. Announces Approval of New Triple-Combination Topical Gel for Acne Treatment
LAVAL, QC / ACCESSWIRE / September 11, 2024
Bausch Health, Canada Inc., part of Bausch Health Companies Inc., has recently announced the approval by Health Canada of PrCABTREOTM (clindamycin phosphate, adapalene, and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%. This new triple-combination topical prescription treatment is designed for patients 12 years of age and older who suffer from acne vulgaris.
CABTREO is groundbreaking in its approach as the first and only triple-combination topical treatment for acne approved by Health Canada. It combines three powerful mechanisms of action – an antibiotic, a retinoid, and an antibacterial agent – to provide a safe and effective treatment for acne. This innovative product showcases Bausch Health’s dedication to bringing advanced dermatology treatments to Canadians.
“The approval of CABTREO demonstrates Bausch Health’s ongoing commitment to providing cutting-edge dermatology solutions,” said Amy Cairns, Vice-President, Commercial and General Manager, Canada, Bausch Health. “We are proud to offer this first triple-combination topical acne treatment to millions of Canadians who struggle with acne each year.”
… (content continues)
How Will This Affect Me?
Having access to a triple-combination topical gel like CABTREO could greatly benefit individuals dealing with acne by offering a more comprehensive and effective treatment option. This innovative product may help improve skin health, boost confidence, and enhance overall well-being for those who struggle with acne.
How Will This Affect the World?
The approval of CABTREO by Health Canada represents a significant advancement in the field of dermatology treatment. This innovative triple-combination topical gel has the potential to revolutionize acne care not only in Canada but globally. By offering a safe and effective solution for acne vulgaris, CABTREO may contribute to improved skin health and quality of life for individuals worldwide.
Conclusion
With the approval of CABTREO by Health Canada, Bausch Health has introduced a groundbreaking triple-combination topical gel for acne treatment. This innovative product showcases the company’s commitment to providing advanced dermatology solutions and may have a positive impact on individuals dealing with acne. The approval of CABTREO represents a significant advancement in dermatology treatment and has the potential to benefit individuals globally.
